Cantor Fitzgerald Reiterates Overweight on Mainz Biomed, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Ross Osborn has reiterated an Overweight rating on Mainz Biomed (NASDAQ:MYNZ) and maintained a $9 price target.
September 26, 2023 | 3:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Ross Osborn has reiterated an Overweight rating on Mainz Biomed and maintained a $9 price target.
The reiteration of an Overweight rating and a $9 price target by Cantor Fitzgerald indicates a positive outlook for Mainz Biomed. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100